Healthcare Triangle, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Healthcare Triangle, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.89M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.70M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $33.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $45.89M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | $35.27M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $31.34M | Mar 8, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Apr 16, 2026 |
| FY2024 | Dec 31, 2024 | $1.07B | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $1.07B | Feb 18, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.48M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($5.97M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($8.69M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.36M) | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | ($5.95M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.35M | Mar 8, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.79M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($4.75M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.32M) | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | ($5.36M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.18M | Mar 8, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $536.0K | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $429.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $799.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.14M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | $5.26M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.74M | Mar 8, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.52M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.08M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($2.15M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.35M) | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | ($7.11M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($734.7K) | Mar 8, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $12.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $40.0K | Feb 18, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.74M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.96M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $6.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.26M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | $24.61M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $11.11M | Mar 8, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.08M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $8.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.22M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | $8.48M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $6.78M | Mar 8, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($5.11M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($1.39M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $6.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $14.24M | Feb 18, 2025 |
| FY2021 | Dec 31, 2020 | $4.33M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $1.97M | Mar 8, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.95M | Apr 16, 2026 |
| FY2025 | Jun 16, 2025 | $2.95M | Apr 16, 2026 |
| FY2023 | Dec 31, 2022 | $1.29M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $1.29M | Mar 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.00M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($33.57M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($27.60M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.92M) | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | ($2.66M) | Mar 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.63M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $20.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.23M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.34M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | $1.77M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.40M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $974.8K | Mar 8, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (152) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | (16,909) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 18, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (152) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | (16,909) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 18, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142,426 | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 380 | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 4.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.17M | Feb 18, 2025 |
| FY2022 | Dec 31, 2021 | 35.26M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 27.90M | Mar 8, 2022 |